Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...

[1] The clinical issues in PCOS relate to ... such as late-onset congenital adrenal hyperplasia and Cushing's syndrome. The more recent 2003 Rotterdam consensus workshop was in response to an ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel analysts kept the price target steady at $166.00 and reiterated a Buy rating.

These sales were executed under a Rule 10b5-1 trading plan adopted ... received FDA approval for treating congenital adrenal hyperplasia (CAH), a significant step forward. Piper Sandler, an ...

Genetic counseling is essential, especially since this disease affects many individuals at reproductive age (1–3). In spite of the fact that this disorder results from a continuum of enzymatic ...

The incidence of genital ambiguity that results in the child’s sex being uncertain is 1 per 4500, 1 although some degree ... pressure should be assessed as various forms of congenital adrenal ...

According to the Centers for Disease Control and Prevention, congenital heart defects are present at birth, affecting around 1% of babies. It is the most common birth defect in the country ...